SEC Info - Pura Naturals, Inc. - ‘10-Q’ for 9/30/19

SEC Info℠

Home

Help

Please Sign In

Pura Naturals, Inc. – ‘10-Q’ for 9/30/19 – ‘EX-101.CAL’

On: Tuesday, 1/21/20, at 3:44pm ET · For: 9/30/19 · Accession #: 1079974-20-44 · File #: 0-54888

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 1/21/20  Pura Naturals, Inc.               10-Q        9/30/19   63:2.4M                                   Edgar.Tech Fili… Svcs/FA

Quarterly Report — Form 10-Q — Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML    249K 
 2: EX-21       Subsidiaries List                                   HTML     17K 
 3: EX-31       Certification -- §302 - SOA'02                      HTML     22K 
 4: EX-32       Certification -- §906 - SOA'02                      HTML     22K 
 5: EX-32       Certification -- §906 - SOA'02                      HTML     18K 
 6: EX-32       Certification Pursuant to                           HTML     19K 
47: R1          Document and Entity Information                     HTML     51K 
15: R2          Consolidated Balance Sheets (Unaudited)             HTML     86K 
34: R3          Consolidated Balance Sheets (Unaudited)             HTML     33K 
                (Parenthetical)                                                  
52: R4          Consolidated Statements of Operations (Unaudited)   HTML     64K 
46: R5          Consolidated Statements of Stockholders? Deficit    HTML     81K 
                (Unaudited)                                                      
14: R6          Consolidated Statements of Cash Flows (Unaudited)   HTML    107K 
32: R7          Organization and Basis of Presentation              HTML     27K 
54: R8          Summary of Significant Accounting Policies          HTML     31K 
44: R9          Going Concern                                       HTML     27K 
60: R10         Intangible Assets                                   HTML     28K 
40: R11         Related Party Transactions                          HTML     24K 
24: R12         Fair Value Measurement                              HTML     34K 
29: R13         Derivative Liabilities                              HTML     30K 
59: R14         Convertible Notes Payable                           HTML     36K 
39: R15         Notes Payable                                       HTML     25K 
23: R16         Stockholders' Equity                                HTML     40K 
28: R17         Concentrations                                      HTML     22K 
61: R18         Commitments and Contingencies                       HTML     22K 
38: R19         Subsequent Events                                   HTML     21K 
17: R20         Summary of Significant Accounting Policies          HTML     42K 
                (Policies)                                                       
31: R21         Summary of Significant Accounting Policies          HTML     23K 
                (Tables)                                                         
56: R22         Intangible Assets (Tables)                          HTML     30K 
45: R23         Fair Value Measurement (Tables)                     HTML     30K 
16: R24         Derivative Liabilities (Tables)                     HTML     31K 
30: R25         Convertible Notes Payable (Tables)                  HTML     36K 
55: R26         Notes Payable (Tables)                              HTML     25K 
43: R27         Stockholders' Equity (Tables)                       HTML     30K 
13: R28         Organization and Basis of Presentation (Details     HTML     30K 
                Narrative)                                                       
33: R29         Summary of Significant Accounting Policies          HTML     25K 
                (Details)                                                        
26: R30         Summary Significant Accounting Policies (Details    HTML     21K 
                Narrative)                                                       
20: R31         Going Concern (Details Narrative)                   HTML     27K 
41: R32         Intangible assets (Details)                         HTML     30K 
62: R33         Intangible Assets (Details 1)                       HTML     35K 
27: R34         Intangible Assets (Details Narrative)               HTML     21K 
21: R35         Related Party Transactions (Details Narrative)      HTML     39K 
42: R36         Fair Value Measurement (Details)                    HTML     23K 
63: R37         Fair Value Measurement (Details Narrative)          HTML     21K 
25: R38         Derivative Liabilities (Details)                    HTML     26K 
22: R39         Derivative Liabilities (Details 1)                  HTML     35K 
36: R40         Convertible Notes Payable (Details)                 HTML     86K 
18: R41         Convertible Notes Payable (Details 1)               HTML     32K 
50: R42         Convertible Note Payable (Details Narratives)       HTML     24K 
57: R43         Notes Payable (Details)                             HTML     38K 
37: R44         Stockholders' Equity (Details)                      HTML     54K 
19: R45         Stockholders' Equity (Details Narrative)            HTML     62K 
51: R46         Concentrations (Details Narrative)                  HTML     33K 
58: R47         Commitments and Contingencies (Details Narrative)   HTML     20K 
35: R48         Subsequent Events (Details Narrative)               HTML     25K 
53: XML         IDEA XML File -- Filing Summary                      XML    108K 
49: EXCEL       IDEA Workbook of Financial Reports                  XLSX     53K 
 7: EX-101.INS  XBRL Instance -- pnat-20190930                       XML    713K 
 9: EX-101.CAL  XBRL Calculations -- pnat-20190930_cal               XML    115K 
10: EX-101.DEF  XBRL Definitions -- pnat-20190930_def                XML    244K 
11: EX-101.LAB  XBRL Labels -- pnat-20190930_lab                     XML    566K 
12: EX-101.PRE  XBRL Presentations -- pnat-20190930_pre              XML    472K 
 8: EX-101.SCH  XBRL Schema -- pnat-20190930                         XSD    117K 
48: ZIP         XBRL Zipped Folder -- 0001079974-20-000044-xbrl      Zip     71K

‘EX-101.CAL’ — XBRL Calculations — pnat-20190930_cal

This Exhibit is an XBRL XML File.

<?xml version="1.0" standalone="no" encoding="windows-1252"?>

<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">

<link:roleRef roleURI="http://puranaturalsproducts.com/role/DocumentAndEntityInformation" xlink:href="pnat-20190930.xsd#DocumentAndEntityInformation" xlink:type="simple"/>

<link:roleRef roleURI="http://puranaturalsproducts.com/role/BalanceSheets" xlink:href="pnat-20190930.xsd#BalanceSheets" xlink:type="simple"/>

<link:roleRef roleURI="http://puranaturalsproducts.com/role/BalanceSheetsParenthetical" xlink:href="pnat-20190930.xsd#BalanceSheetsParenthetical" xlink:type="simple"/>

<link:roleRef roleURI="http://puranaturalsproducts.com/role/StatementsOfOperations" xlink:href="pnat-20190930.xsd#StatementsOfOperations" xlink:type="simple"/>

<link:roleRef roleURI="http://puranaturalsproducts.com/role/StatementsOfStockholdersDeficit" xlink:href="pnat-20190930.xsd#StatementsOfStockholdersDeficit" xlink:type="simple"/>

<link:roleRef roleURI="http://puranaturalsproducts.com/role/StatementsOfCashFlows" xlink:href="pnat-20190930.xsd#StatementsOfCashFlows" xlink:type="simple"/>

<link:roleRef roleURI="http://puranaturalsproducts.com/role/OrganizationAndBasisOfPresentation" xlink:href="pnat-20190930.xsd#OrganizationAndBasisOfPresentation" xlink:type="simple"/>

<link:roleRef roleURI="http://puranaturalsproducts.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="pnat-20190930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple"/>

<link:roleRef roleURI="http://puranaturalsproducts.com/role/GoingConcern" xlink:href="pnat-20190930.xsd#GoingConcern" xlink:type="simple"/>

<link:roleRef roleURI="http://puranaturalsproducts.com/role/IntangibleAssets" xlink:href="pnat-20190930.xsd#IntangibleAssets" xlink:type="simple"/>

<link:roleRef roleURI="http://puranaturalsproducts.com/role/RelatedPartyTransactions" xlink:href="pnat-20190930.xsd#RelatedPartyTransactions" xlink:type="simple"/>

<link:roleRef roleURI="http://puranaturalsproducts.com/role/FairValueMeasurement" xlink:href="pnat-20190930.xsd#FairValueMeasurement" xlink:type="simple"/>

<link:roleRef roleURI="http://puranaturalsproducts.com/role/DerivativeLiabilities" xlink:href="pnat-20190930.xsd#DerivativeLiabilities" xlink:type="simple"/>

<link:roleRef roleURI="http://puranaturalsproducts.com/role/ConvertibleNotesPayable" xlink:href="pnat-20190930.xsd#ConvertibleNotesPayable" xlink:type="simple"/>

<link:roleRef roleURI="http://puranaturalsproducts.com/role/NotesPayable" xlink:href="pnat-20190930.xsd#NotesPayable" xlink:type="simple"/>

<link:roleRef roleURI="http://puranaturalsproducts.com/role/StockholdersEquity" xlink:href="pnat-20190930.xsd#StockholdersEquity" xlink:type="simple"/>

<link:roleRef roleURI="http://puranaturalsproducts.com/role/Concentrations" xlink:href="pnat-20190930.xsd#Concentrations" xlink:type="simple"/>

<link:roleRef roleURI="http://puranaturalsproducts.com/role/CommitmentsAndContingencies" xlink:href="pnat-20190930.xsd#CommitmentsAndContingencies" xlink:type="simple"/>

<link:roleRef roleURI="http://puranaturalsproducts.com/role/SubsequentEvents" xlink:href="pnat-20190930.xsd#SubsequentEvents" xlink:type="simple"/>

<link:roleRef roleURI="http://puranaturalsproducts.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="pnat-20190930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>

<link:roleRef roleURI="http://puranaturalsproducts.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="pnat-20190930.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple"/>

<link:roleRef roleURI="http://puranaturalsproducts.com/role/IntangibleAssetsTables" xlink:href="pnat-20190930.xsd#IntangibleAssetsTables" xlink:type="simple"/>

<link:roleRef roleURI="http://puranaturalsproducts.com/role/FairValueMeasurementTables" xlink:href="pnat-20190930.xsd#FairValueMeasurementTables" xlink:type="simple"/>

<link:roleRef roleURI="http://puranaturalsproducts.com/role/DerivativeLiabilitiesTables" xlink:href="pnat-20190930.xsd#DerivativeLiabilitiesTables" xlink:type="simple"/>

<link:roleRef roleURI="http://puranaturalsproducts.com/role/ConvertibleNotesPayableTables" xlink:href="pnat-20190930.xsd#ConvertibleNotesPayableTables" xlink:type="simple"/>

<link:roleRef roleURI="http://puranaturalsproducts.com/role/NotesPayableTables" xlink:href="pnat-20190930.xsd#NotesPayableTables" xlink:type="simple"/>

<link:roleRef roleURI="http://puranaturalsproducts.com/role/StockholdersEquityTables" xlink:href="pnat-20190930.xsd#StockholdersEquityTables" xlink:type="simple"/>

<link:roleRef roleURI="http://puranaturalsproducts.com/role/OrganizationAndBasisOfPresentationDetailsNarrative" xlink:href="pnat-20190930.xsd#OrganizationAndBasisOfPresentationDetailsNarrative" xlink:type="simple"/>

<link:roleRef roleURI="http://puranaturalsproducts.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="pnat-20190930.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple"/>

<link:roleRef roleURI="http://puranaturalsproducts.com/role/SummarySignificantAccountingPoliciesDetailsNarrative" xlink:href="pnat-20190930.xsd#SummarySignificantAccountingPoliciesDetailsNarrative" xlink:type="simple"/>

<link:roleRef roleURI="http://puranaturalsproducts.com/role/GoingConcernDetailsNarrative" xlink:href="pnat-20190930.xsd#GoingConcernDetailsNarrative" xlink:type="simple"/>

<link:roleRef roleURI="http://puranaturalsproducts.com/role/IntangibleAssetsDetails" xlink:href="pnat-20190930.xsd#IntangibleAssetsDetails" xlink:type="simple"/>

<link:roleRef roleURI="http://puranaturalsproducts.com/role/IntangibleAssetsDetails1" xlink:href="pnat-20190930.xsd#IntangibleAssetsDetails1" xlink:type="simple"/>

<link:roleRef roleURI="http://puranaturalsproducts.com/role/IntangibleAssetsDetailsNarrative" xlink:href="pnat-20190930.xsd#IntangibleAssetsDetailsNarrative" xlink:type="simple"/>

<link:roleRef roleURI="http://puranaturalsproducts.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="pnat-20190930.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple"/>

<link:roleRef roleURI="http://puranaturalsproducts.com/role/FairValueMeasurementDetails" xlink:href="pnat-20190930.xsd#FairValueMeasurementDetails" xlink:type="simple"/>

<link:roleRef roleURI="http://puranaturalsproducts.com/role/FairValueMeasurementDetailsNarrative" xlink:href="pnat-20190930.xsd#FairValueMeasurementDetailsNarrative" xlink:type="simple"/>

<link:roleRef roleURI="http://puranaturalsproducts.com/role/DerivativeLiabilitiesDetails" xlink:href="pnat-20190930.xsd#DerivativeLiabilitiesDetails" xlink:type="simple"/>

<link:roleRef roleURI="http://puranaturalsproducts.com/role/DerivativeLiabilitiesDetails1" xlink:href="pnat-20190930.xsd#DerivativeLiabilitiesDetails1" xlink:type="simple"/>

<link:roleRef roleURI="http://puranaturalsproducts.com/role/ConvertibleNotesPayableDetails" xlink:href="pnat-20190930.xsd#ConvertibleNotesPayableDetails" xlink:type="simple"/>

<link:roleRef roleURI="http://puranaturalsproducts.com/role/ConvertibleNotesPayableDetails1" xlink:href="pnat-20190930.xsd#ConvertibleNotesPayableDetails1" xlink:type="simple"/>

<link:roleRef roleURI="http://puranaturalsproducts.com/role/ConvertibleNotePayableDetailsNarratives" xlink:href="pnat-20190930.xsd#ConvertibleNotePayableDetailsNarratives" xlink:type="simple"/>

<link:roleRef roleURI="http://puranaturalsproducts.com/role/NotesPayableDetails" xlink:href="pnat-20190930.xsd#NotesPayableDetails" xlink:type="simple"/>

<link:roleRef roleURI="http://puranaturalsproducts.com/role/StockholdersEquityDetails" xlink:href="pnat-20190930.xsd#StockholdersEquityDetails" xlink:type="simple"/>

<link:roleRef roleURI="http://puranaturalsproducts.com/role/StockholdersEquityDetailsNarrative" xlink:href="pnat-20190930.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple"/>

<link:roleRef roleURI="http://puranaturalsproducts.com/role/ConcentrationsDetailsNarrative" xlink:href="pnat-20190930.xsd#ConcentrationsDetailsNarrative" xlink:type="simple"/>

<link:roleRef roleURI="http://puranaturalsproducts.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="pnat-20190930.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple"/>

<link:roleRef roleURI="http://puranaturalsproducts.com/role/SubsequentEventsDetailsNarrative" xlink:href="pnat-20190930.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple"/>

<link:calculationLink xlink:type="extended" xlink:role="http://puranaturalsproducts.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information"/>

<link:calculationLink xlink:type="extended" xlink:role="http://puranaturalsproducts.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets (Unaudited)">

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash"/>

<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCash" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNet" xlink:label="loc_us-gaapAccountsReceivableNet"/>

<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsReceivableNet" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent"/>

<link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet"/>

<link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssets" xlink:label="loc_us-gaapOtherAssets"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet"/>

<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAssets" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets"/>

<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1"/>

<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOtherAssets" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent"/>

<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent"/>

<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaapDueToRelatedPartiesCurrent"/>

<link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDueToRelatedPartiesCurrent" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaapDeferredRevenueCurrent"/>

<link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDeferredRevenueCurrent" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent"/>

<link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapNotesPayableCurrent" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent"/>

<link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaapConvertibleNotesPayableCurrent"/>

<link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapConvertibleNotesPayableCurrent" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities"/>

<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue"/>

<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital"/>

<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit"/>

<link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity"/>

<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1"/>

<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1"/>

</link:calculationLink>

<link:calculationLink xlink:type="extended" xlink:role="http://puranaturalsproducts.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://puranaturalsproducts.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations (Unaudited)">

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues"/>

<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapRevenues" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue"/>

<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapCostOfRevenue" xlink:type="arc" weight="-1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingExpense" xlink:label="loc_us-gaapSellingExpense"/>

<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapSellingExpense" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense"/>

<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss"/>

<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1"/>

<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense"/>

<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" weight="-1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:label="loc_us-gaapFairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss"/>

<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:to="loc_us-gaapFairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>

<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit"/>

<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1"/>

</link:calculationLink>

<link:calculationLink xlink:type="extended" xlink:role="http://puranaturalsproducts.com/role/StatementsOfStockholdersDeficit" xlink:title="00000005 - Statement - Consolidated Statements of Stockholders’ Deficit (Unaudited)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://puranaturalsproducts.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows (Unaudited)">

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets"/>

<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" weight="-1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="loc_us-gaapRepaymentsOfConvertibleDebt"/>

<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfConvertibleDebt" xlink:type="arc" weight="-1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:label="loc_us-gaapProceedsFromRepaymentsOfNotesPayable"/>

<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromRepaymentsOfNotesPayable" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt"/>

<link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromConvertibleDebt" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity"/>

<link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable"/>

<link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromNotesPayable" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities"/>

<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1"/>

<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1"/>

<link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1"/>

</link:calculationLink>

<link:calculationLink xlink:type="extended" xlink:role="http://puranaturalsproducts.com/role/OrganizationAndBasisOfPresentation" xlink:title="00000007 - Disclosure - Organization and Basis of Presentation"/>

<link:calculationLink xlink:type="extended" xlink:role="http://puranaturalsproducts.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - Summary of Significant Accounting Policies"/>

<link:calculationLink xlink:type="extended" xlink:role="http://puranaturalsproducts.com/role/GoingConcern" xlink:title="00000009 - Disclosure - Going Concern"/>

<link:calculationLink xlink:type="extended" xlink:role="http://puranaturalsproducts.com/role/IntangibleAssets" xlink:title="00000010 - Disclosure - Intangible Assets"/>

<link:calculationLink xlink:type="extended" xlink:role="http://puranaturalsproducts.com/role/RelatedPartyTransactions" xlink:title="00000011 - Disclosure - Related Party Transactions"/>

<link:calculationLink xlink:type="extended" xlink:role="http://puranaturalsproducts.com/role/FairValueMeasurement" xlink:title="00000012 - Disclosure - Fair Value Measurement"/>

<link:calculationLink xlink:type="extended" xlink:role="http://puranaturalsproducts.com/role/DerivativeLiabilities" xlink:title="00000013 - Disclosure - Derivative Liabilities"/>

<link:calculationLink xlink:type="extended" xlink:role="http://puranaturalsproducts.com/role/ConvertibleNotesPayable" xlink:title="00000014 - Disclosure - Convertible Notes Payable"/>

<link:calculationLink xlink:type="extended" xlink:role="http://puranaturalsproducts.com/role/NotesPayable" xlink:title="00000015 - Disclosure - Notes Payable"/>

<link:calculationLink xlink:type="extended" xlink:role="http://puranaturalsproducts.com/role/StockholdersEquity" xlink:title="00000016 - Disclosure - Stockholders' Equity"/>

<link:calculationLink xlink:type="extended" xlink:role="http://puranaturalsproducts.com/role/Concentrations" xlink:title="00000017 - Disclosure - Concentrations"/>

<link:calculationLink xlink:type="extended" xlink:role="http://puranaturalsproducts.com/role/CommitmentsAndContingencies" xlink:title="00000018 - Disclosure - Commitments and Contingencies"/>

<link:calculationLink xlink:type="extended" xlink:role="http://puranaturalsproducts.com/role/SubsequentEvents" xlink:title="00000019 - Disclosure - Subsequent Events"/>

<link:calculationLink xlink:type="extended" xlink:role="http://puranaturalsproducts.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000020 - Disclosure - Summary of Significant Accounting Policies (Policies)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://puranaturalsproducts.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000021 - Disclosure - Summary of Significant Accounting Policies (Tables)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://puranaturalsproducts.com/role/IntangibleAssetsTables" xlink:title="00000022 - Disclosure - Intangible Assets (Tables)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://puranaturalsproducts.com/role/FairValueMeasurementTables" xlink:title="00000023 - Disclosure - Fair Value Measurement (Tables)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://puranaturalsproducts.com/role/DerivativeLiabilitiesTables" xlink:title="00000024 - Disclosure - Derivative Liabilities (Tables)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://puranaturalsproducts.com/role/ConvertibleNotesPayableTables" xlink:title="00000025 - Disclosure - Convertible Notes Payable (Tables)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://puranaturalsproducts.com/role/NotesPayableTables" xlink:title="00000026 - Disclosure - Notes Payable (Tables)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://puranaturalsproducts.com/role/StockholdersEquityTables" xlink:title="00000027 - Disclosure - Stockholders' Equity (Tables)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://puranaturalsproducts.com/role/OrganizationAndBasisOfPresentationDetailsNarrative" xlink:title="00000028 - Disclosure - Organization and Basis of Presentation (Details Narrative)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://puranaturalsproducts.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:title="00000029 - Disclosure - Summary of Significant Accounting Policies (Details)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://puranaturalsproducts.com/role/SummarySignificantAccountingPoliciesDetailsNarrative" xlink:title="00000030 - Disclosure - Summary Significant Accounting Policies (Details Narrative)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://puranaturalsproducts.com/role/GoingConcernDetailsNarrative" xlink:title="00000031 - Disclosure - Going Concern (Details Narrative)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://puranaturalsproducts.com/role/IntangibleAssetsDetails" xlink:title="00000032 - Disclosure - Intangible assets (Details)">

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedContractualRightsGross" xlink:label="loc_us-gaapFiniteLivedContractualRightsGross"/>

<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsGross" xlink:to="loc_us-gaapFiniteLivedContractualRightsGross" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedTrademarks" xlink:label="loc_us-gaapIndefiniteLivedTrademarks"/>

<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsGross" xlink:to="loc_us-gaapIndefiniteLivedTrademarks" xlink:type="arc" weight="1"/>

<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization"/>

<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" weight="-1"/>

</link:calculationLink>

<link:calculationLink xlink:type="extended" xlink:role="http://puranaturalsproducts.com/role/IntangibleAssetsDetails1" xlink:title="00000033 - Disclosure - Intangible Assets (Details 1)">

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>

<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>

<link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>

<link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>

<link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>

<link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" weight="1"/>

</link:calculationLink>

<link:calculationLink xlink:type="extended" xlink:role="http://puranaturalsproducts.com/role/IntangibleAssetsDetailsNarrative" xlink:title="00000034 - Disclosure - Intangible Assets (Details Narrative)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://puranaturalsproducts.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000035 - Disclosure - Related Party Transactions (Details Narrative)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://puranaturalsproducts.com/role/FairValueMeasurementDetails" xlink:title="00000036 - Disclosure - Fair Value Measurement (Details)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://puranaturalsproducts.com/role/FairValueMeasurementDetailsNarrative" xlink:title="00000037 - Disclosure - Fair Value Measurement (Details Narrative)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://puranaturalsproducts.com/role/DerivativeLiabilitiesDetails" xlink:title="00000038 - Disclosure - Derivative Liabilities (Details)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://puranaturalsproducts.com/role/DerivativeLiabilitiesDetails1" xlink:title="00000039 - Disclosure - Derivative Liabilities (Details 1)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://puranaturalsproducts.com/role/ConvertibleNotesPayableDetails" xlink:title="00000040 - Disclosure - Convertible Notes Payable (Details)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://puranaturalsproducts.com/role/ConvertibleNotesPayableDetails1" xlink:title="00000041 - Disclosure - Convertible Notes Payable (Details 1)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://puranaturalsproducts.com/role/ConvertibleNotePayableDetailsNarratives" xlink:title="00000042 - Disclosure - Convertible Note Payable (Details Narratives)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://puranaturalsproducts.com/role/NotesPayableDetails" xlink:title="00000043 - Disclosure - Notes Payable (Details)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://puranaturalsproducts.com/role/StockholdersEquityDetails" xlink:title="00000044 - Disclosure - Stockholders' Equity (Details)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://puranaturalsproducts.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000045 - Disclosure - Stockholders' Equity (Details Narrative)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://puranaturalsproducts.com/role/ConcentrationsDetailsNarrative" xlink:title="00000046 - Disclosure - Concentrations (Details Narrative)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://puranaturalsproducts.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000047 - Disclosure - Commitments and Contingencies (Details Narrative)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://puranaturalsproducts.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000048 - Disclosure - Subsequent Events (Details Narrative)"/>

</link:linkbase>

↑Top

Filing Submission 0001079974-20-000044 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Pura Naturals, Inc. – ‘10-Q’ for 9/30/19 – ‘EX-101.CAL’

On: Tuesday, 1/21/20, at 3:44pm ET · For: 9/30/19 · Accession #: 1079974-20-44 · File #: 0-54888

Previous ‘10-Q’: ‘10-Q’ on 9/13/19 for 6/30/19 · Latest ‘10-Q’: This Filing

Quarterly Report — Form 10-Q — Sect. 13 / 15(d) – SEA’34Filing Table of Contents

‘EX-101.CAL’ — XBRL Calculations — pnat-20190930_cal

This Exhibit is an XBRL XML File.

Quarterly Report — Form 10-Q — Sect. 13 / 15(d) – SEA’34
Filing Table of Contents